| Fibroblast growth factor 21 corrects obesity in mice T Coskun, HA Bina, MA Schneider, JD Dunbar, CC Hu, Y Chen, ... Endocrinology 149 (12), 6018-6027, 2008 | 1224 | 2008 |
| Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms N I˙ meryüz, BC Yeğen, A Bozkurt, T Coşkun, ... American Journal of Physiology-Gastrointestinal and Liver Physiology 273 (4 …, 1997 | 563 | 1997 |
| The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL PJ Emmerson, F Wang, Y Du, Q Liu, RT Pickard, MD Gonciarz, T Coskun, ... Nature medicine 23 (10), 1215-1219, 2017 | 501 | 2017 |
| Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa A Stengel, M Goebel, I Yakubov, L Wang, D Witcher, T Coskun, Y Taché, ... Endocrinology 150 (1), 232-238, 2009 | 498 | 2009 |
| LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept T Coskun, KW Sloop, C Loghin, J Alsina-Fernandez, S Urva, KB Bokvist, ... Molecular metabolism 18, 3-14, 2018 | 492 | 2018 |
| FGF‐21/FGF‐21 receptor interaction and activation is determined by βKlotho A Kharitonenkov, JD Dunbar, HA Bina, S Bright, JS Moyers, C Zhang, ... Journal of cellular physiology 215 (1), 1-7, 2008 | 394 | 2008 |
| The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue AC Adams, C Yang, T Coskun, CC Cheng, RE Gimeno, Y Luo, ... Molecular metabolism 2 (1), 31-37, 2013 | 288 | 2013 |
| Triple–hormone-receptor agonist retatrutide for obesity—a phase 2 trial AM Jastreboff, LM Kaplan, JP Frías, Q Wu, Y Du, S Gurbuz, T Coskun, ... New England Journal of Medicine 389 (6), 514-526, 2023 | 213 | 2023 |
| FGF21 Requires βklotho to Act In Vivo AC Adams, CC Cheng, T Coskun, A Kharitonenkov PloS one 7 (11), e49977, 2012 | 213 | 2012 |
| Secretin-activated brown fat mediates prandial thermogenesis to induce satiation Y Li, K Schnabl, SM Gabler, M Willershäuser, J Reber, A Karlas, S Laurila, ... Cell 175 (6), 1561-1574. e12, 2018 | 200 | 2018 |
| Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319 A Kharitonenkov, JM Beals, R Micanovic, BA Strifler, R Rathnachalam, ... PloS one 8 (3), e58575, 2013 | 181 | 2013 |
| Fundamentals of FGF19 & FGF21 Action In Vitro and In Vivo AC Adams, T Coskun, AR Irizarry Rovira, MA Schneider, DW Raches, ... PloS one 7 (5), e38438, 2012 | 128 | 2012 |
| Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised … T Heise, A Mari, JH DeVries, S Urva, J Li, EJ Pratt, T Coskun, MK Thomas, ... The Lancet Diabetes & Endocrinology 10 (6), 418-429, 2022 | 122 | 2022 |
| Preproghrelin‐derived peptide, obestatin, fails to influence food intake in lean or obese rodents G Gourcerol, T Coskun, LS Craft, JP Mayer, ML Heiman, L Wang, ... Obesity 15 (11), 2643-2652, 2007 | 101 | 2007 |
| LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept T Coskun, S Urva, WC Roell, H Qu, C Loghin, JS Moyers, LS O’Farrell, ... Cell metabolism 34 (9), 1234-1247. e9, 2022 | 99 | 2022 |
| The GPR 120 agonist TUG‐891 promotes metabolic health by stimulating mitochondrial respiration in brown fat M Schilperoort, AD van Dam, G Hoeke, IG Shabalina, A Okolo, ... EMBO molecular medicine 10 (3), e8047, 2018 | 94 | 2018 |
| κ-Opioid receptors control the metabolic response to a high-energy diet in mice TA Czyzyk, R Nogueiras, JF Lockwood, JH McKinzie, T Coskun, JE Pintar, ... The FASEB Journal 24 (4), 1151, 2010 | 94 | 2010 |
| Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 … J Rosenstock, J Frias, AM Jastreboff, Y Du, J Lou, S Gurbuz, MK Thomas, ... The Lancet 402 (10401), 529-544, 2023 | 92 | 2023 |
| LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised … S Urva, T Coskun, MT Loh, Y Du, MK Thomas, S Gurbuz, A Haupt, ... The Lancet 400 (10366), 1869-1881, 2022 | 92 | 2022 |
| Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression DR Gehlert, K Rasmussen, J Shaw, X Li, P Ardayfio, L Craft, T Coskun, ... Journal of Pharmacology and Experimental Therapeutics 329 (2), 429-438, 2009 | 92 | 2009 |
